Computed from SEC EDGAR filings and closing prices — not copied from any wealth ranking. Dataset . How we calculate this.

Market capitalisation
$8.94B
129,984,169 shares ≈ see note Covers every share class this company has on file.
Insiders on file
11
people who have filed Form 3, 4 or 5 naming this issuer
Value of insider-held stock
$191.47M
from the holdings reported on Forms 3/4/5; this figure has no separate as-of date on file
Insider-held share of market cap
2.14%
insider-held value divided by market capitalisation

What 10x Genomics, Inc. reports

Revenue and net income below are for fiscal period FY2025, the period label carried by this company’s own annual XBRL filings to the SEC. Fiscal years do not line up between companies — one company’s FY2026 can cover much the same months as another’s FY2025 — so compare the periods, not just the numbers.

Revenue
$642.82M
FY2025 annual revenue, from this company’s own annual XBRL filings to the SEC
Net income
-$43.50M
FY2025 a loss for the period, from this company’s own annual XBRL filings to the SEC
Employees
1,178
Yahoo Finance
Where the employee count comes from

Headcount comes from Yahoo Finance, not from a filing. The date beside it is the day we retrieved the figure — it is not the date the company counted its staff, and Yahoo does not publish that date. Unlike the SEC filings behind the other figures on this page, this one carries no open licence, so we publish the number and nothing else from that source.

Insiders at 10x Genomics, Inc.

Shares is what each person last reported holding here.

Everyone below has filed at least one insider report against this company.

Value is that share count priced at the same closing price used everywhere else on this site. A row priced from only some of a person’s securities says so — we do not quietly present a partial sum as a complete one.

Rows are grouped by the role each person reports.

The role comes from the relationship boxes a person ticks on their own insider filings — officer, director, ten per cent owner — not from anything we infer. Somebody who is both an officer and a director appears once, in the combined group, so the row count still matches the figure at the top of this page. Where no filing states a role we say so instead of guessing one.

People who file insider reports against 10x Genomics, Inc..
Insider Reported role Shares Value Last action
Officers 2
Adam Taich CFO 394,996 $24.75M S Open-market sale Sep 9, 2026 position reported
Justin J McAnear CFO 143,242 $8.97M S Open-market sale Aug 22, 2024 position reported
Officers who also sit on the board 3
Serge Saxonov CEO 1,243,917 $77.93M G Bona fide gift Sep 1, 2026 position reported
Benjamin J Hindson Executive 513,595 $32.18M S Open-market sale Aug 24, 2026 position reported
Alan Mateo EVP 77,048 $4.83M A Grant or award Jun 4, 2026 position reported
Directors 6
John R. Stuelpnagel Board Member 359,607 $22.53M S Open-market sale Sep 3, 2026 position reported
Mathai Mammen Board Member 180,259 $11.29M A Grant or award Jun 11, 2024 position reported
Sridhar Kosaraju Board Member 59,449 $3.72M A Grant or award Jun 4, 2026 position reported
Kimberly J Popovits Board Member 28,616 $1.79M A Grant or award Jun 4, 2026 position reported
Shehnaaz Suliman Shehnaaz Suliman Board Member 28,616 $1.79M S Open-market sale Aug 24, 2026 position reported
Sarah A Teichmann Board Member 26,780 $1.68M S Open-market sale Aug 14, 2026 position reported

Recent insider transactions

Of the 96 rows we hold, 1 are open-market purchases (P) and 57 open-market sales (S) — the only codes we count as buying or selling.

The rest — awards, shares withheld to pay tax, option exercises, gifts and so on — follow from an employment contract or a transfer arranged off-market, not from a decision to buy or sell, so counting them would turn this into a pay table.

A price of 0.00 is a real reported figure on gifts (G) and share awards (A) — not a gap in our data.

Insider transactions disclosed to the SEC for 10x Genomics, Inc., newest first, each with the filing behind it.
Date Insider Transaction Shares Price Value Filing
Jun 16, 2026 Shehnaaz Suliman S Open-market sale 5,359 $32.59 $174.6K SEC filing ↗
Jun 4, 2026 Sarah A Teichmann A Grant or award 8,829 $0.00 $0 SEC filing ↗
Jun 4, 2026 Shehnaaz Suliman A Grant or award 8,829 $0.00 $0 SEC filing ↗
Jun 4, 2026 John R. Stuelpnagel A Grant or award 8,829 $0.00 $0 SEC filing ↗
Jun 4, 2026 Kimberly J Popovits A Grant or award 8,829 $0.00 $0 SEC filing ↗
Jun 4, 2026 Alan Mateo A Grant or award 8,829 $0.00 $0 SEC filing ↗
Jun 4, 2026 Sridhar Kosaraju A Grant or award 8,829 $0.00 $0 SEC filing ↗
May 26, 2026 Serge Saxonov S Open-market sale 10,718 $24.71 $264.8K SEC filing ↗
May 22, 2026 Serge Saxonov S Open-market sale 18,175 $24.44 $444.2K SEC filing ↗
May 22, 2026 Benjamin J Hindson S Open-market sale 11,595 $24.44 $283.4K SEC filing ↗
May 22, 2026 Adam Taich S Open-market sale 15,098 $24.44 $369.0K SEC filing ↗
Apr 14, 2026 Serge Saxonov S Open-market sale 5,000 $24.56 $122.8K SEC filing ↗
Mar 24, 2026 Serge Saxonov S Open-market sale 5,000 $19.52 $97.6K SEC filing ↗
Mar 23, 2026 Serge Saxonov S Open-market sale 10,000 $19.13 $191.3K SEC filing ↗
Mar 3, 2026 Serge Saxonov G Bona fide gift 2,750 $0.00 $0 SEC filing ↗
Mar 2, 2026 Serge Saxonov S Open-market sale 1,860 $23.18 $43.1K SEC filing ↗
Mar 2, 2026 Serge Saxonov S Open-market sale 14,292 $22.67 $324.0K SEC filing ↗
Feb 26, 2026 Adam Taich A Grant or award 106,579 $0.00 $0 SEC filing ↗
Feb 26, 2026 Serge Saxonov A Grant or award 157,895 $0.00 $0 SEC filing ↗
Feb 26, 2026 Benjamin J Hindson A Grant or award 88,816 $0.00 $0 SEC filing ↗
Feb 25, 2026 Sarah A Teichmann S Open-market sale 7,579 $19.41 $147.1K SEC filing ↗
Feb 23, 2026 Adam Taich S Open-market sale 8,968 $18.58 $166.6K SEC filing ↗
Feb 23, 2026 Serge Saxonov S Open-market sale 9,632 $18.58 $179.0K SEC filing ↗
Feb 23, 2026 Benjamin J Hindson S Open-market sale 7,826 $18.58 $145.4K SEC filing ↗
Jan 5, 2026 Serge Saxonov M Option exercise or conversion 50,000 $1.20 $60.0K SEC filing ↗

From SEC Form 4 filings. Every row links to the filing it came from. How we calculate this.

What a Form 4 is

The report an officer, director or large shareholder must file after trading their own company’s stock.

Think a number here is wrong? Open the linked filing and compare — how to report it.

Sources and technical notes

Every figure on this page comes from filings to the U.S. SEC via EDGAR. Nothing here is estimated, and nothing is taken from press coverage or company websites.

Share count: weighted average over the reporting period (us-gaap:WeightedAverageNumberOfSharesOutstandingBasic), taken from 10x Genomics, Inc.’s own filings and multiplied by our closing price. Not a single-day figure — treat this market cap and its rank as approximate. Full method.

What that share count means

this company did not tag a cover-page share count we could read, so the figure is the average number of shares outstanding across the whole reporting period rather than a count on any single day. If the company issued or bought back stock during the period, the true count today is higher or lower than this.

We do not take a market cap from a data vendor, and we do not estimate one: the figure is a share count from 10x Genomics, Inc.’s own SEC filings multiplied by the closing price we hold for the same stock.